Stock EPRX EUPRAXIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Eupraxia Pharmaceuticals Inc.

Equities

EPRX

CA29842P1053

Delayed Toronto S.E.
Other stock markets
 09:30:00 2024-06-18 EDT 		5-day change 1st Jan Change
3.65 CAD 0.00% Intraday chart for Eupraxia Pharmaceuticals Inc. -1.08% -32.03%
06-05 Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024 MT
05-23 Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sector Update: Health Care Stocks Lower Premarket Wednesday
Sector Update: Health Care
Eupraxia Pharmaceuticals Announces Data from the Phase 1b/2a RESOLVE Clinical Trial
Eupraxia Pharmaceuticals Reports Positive Data From Eosinophilic Esophagitis Treatment Study -- Shares Rise After Hours
Eupraxia Pharmaceuticals Inc. Announces New Positive Data from Resolve Phase 1B/2A Trial of Ep-104Gi for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Top Premarket Decliners
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IAR
Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the Knee
Eupraxia Pharmaceuticals Inc. Announces Positive Clinical Data in EP-104GI RESOLVE Trial
Eupraxia Pharmaceuticals Down 5.6% After Announcing Clinical and Corporate Update
Eupraxia Pharmaceuticals Inc. Announces Updates for Its Two Clinical Programs, EP-104IAR and EP-104GI
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Eupraxia Pharmaceuticals Inc. Announces Initiation of Second Cohort in Phase 1B/2A Clinical Trial in Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Eupraxia Pharmaceuticals Reports Positive Topline Data in Its Phase 2B Osteoarthritis Trial with Ep-104IAR
Eupraxia Pharmaceuticals Receives U.S. FDA Fast Track Designation for Ep-104Iar in Treatment of Osteoarthritis
Eupraxia Pharmaceuticals Inc. Doses First Patient in Phase 1B/2A Eosinophilic Esophagitis Trial
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EPRX Stock
  4. News Eupraxia Pharmaceuticals Inc.
  5. Other languages